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Although generally benign, pituitary tumors frequently show local invasiveness and
resistance to pharmacological therapy. After the demonstration of the existence of
pituitary gland stem cells, over the past decade, the presence of a stem cell
subpopulation in pituitary tumors has been investigated, analogous to the cancer stem
cell model developed for malignant tumors. This review recapitulates the experimental
evidence supporting the existence of a population of stem-like cells in pituitary tumors,
focusing on their potential role in tumor initiation, progression, recurrence and resistance
to pharmacological therapy.
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INTRODUCTION
Pituitary tumors represent 10–25% of intracranial neoplasms. They can be classified based on their
secretory activity into non-functioning pituitary tumors (NFPTs) or hormone-secreting tumors,
including prolactin (PRL)-, growth hormone (GH)-, and adenocorticotropic hormone (ACTH)-
secreting tumors. Pituitary tumors may cause visual field deficits and neurologic manifestations
from mass effects and/or endocrine syndromes with specific signs and symptoms.
The pathogenetic mechanisms of pituitary tumourigenesis may be genetic or epigenetic
and include cell cycle dysregulation, activation of oncoproteins, alterations in growth factors
signaling, changes in the intrapituitary microenvironment, and germline or somatic mutations
[reviewed in (1)]. In rare cases, germline pathogenetic mutations predispose individuals to pituitary
tumourigenesis, often in the setting of familial genetic syndromes, whereas in the majority of
sporadic cases, the exact molecular pathogenetic mechanism remains unknown.
Neurosurgery by the transsphenoidal approach is the treatment of choice in the majority of
cases, except for PRL-secreting tumors, for which dopamine receptor type 2 (DRD2) agonists (DAs)
represent the first-line therapy. Pharmacological treatment of GH- and ACTH-secreting tumors is
based on the use of somatostatin (SS) analogs (SSAs). However, a subset of patients (approximately
10% of PRL-, 30% of GH-, and 50–70% of ACTH-secreting tumors) is resistant to these drugs (2–5).
Although classified as benign, pituitary tumors are frequently highly invasive into surrounding
tissues (6) and can exhibit clinically aggressive behavior. Invasive tumors are associated with
incomplete tumor resection and a high rate of recurrence (7, 8). Pituitary carcinomas are extremely
rare, accounting for only 0.1–0.2% of pituitary tumors, but the prognosis is very poor, and 66% of
patients die within the first year (9).
Mantovani et al. Pituitary Tumors Stem Cells
The discovery of a population of stem-like cells in pituitary
tumors has raised the question about the role these cells in
tumourigenesis, growth, invasiveness, recurrence and resistance
to pharmacological treatment, similar to the cancer stem cell
(CSC) model theorized for malignant tumors.
CANCER STEM CELLS:
CHARACTERISTICS, MARKERS, AND
THERAPIES
The cancer stem cell model states that tumor initiation,
progression, growth and recurrence are promoted by a
subpopulation of tumor stem cells (10). CSCs were first identified
and studied in human leukemia (11, 12) and then in different
types of solid tumors, including breast (13), brain (14) and liver
(15) cancers. Although most studies have demonstrated that CSC
are relatively rare in a number of tumor types, recent works show
that tumorigenic potential is a common attribute of melanoma
cells (16, 17).
CSCs have indefinite self-renewal capacity, an ability shared
with normal tissue stem cells. However, unlike normal stem
cells, CSCs also have tumor-generating potential (10). Moreover,
CSCs have multilineage differentiation potential and are able to
give rise to progenitors that can differentiate into all cell types
that compose the bulk of the tumor mass. The multipotency of
CSCs provides an explanation for intra-tumor heterogeneity (17).
However, committed cells and even completely differentiated
cells retain the ability to dedifferentiate, suggesting a high
level of plasticity instead of a hierarchical one-direction
differentiation (17). In this scenario, a CSC is considered a
cell state that can switch from stem cell to differentiated cell,
and vice-versa.
Based on the CSCmodel, while CSCs trigger tumor recurrence
and metastatic spreading, the non-CSC population of the tumor
does not contribute to the long-term growth of the tumor, as it
can undergo only transient proliferation. In addition, CSCs are
resistant to chemotherapy and radiotherapy (18) due to their
specific features, e.g., slower rate of proliferation or quiescence
state, small size, high expression of drug efflux pumps, alterations
in apoptosis pathways and expression of telomerase.
The origin of CSCs is still uncertain. It has been proposed that
they derive from the oncogenic transformation of normal tissue-
specific stem cells (19, 20), progenitors or differentiated cells after
reprogramming and dedifferentiation (21).
Signaling pathways that regulate the balance between self-
renewal and differentiation of both normal and cancer stem cells
are classically associated with oncogenesis, such as Notch, Sonic
hedgehog, octamer-binding transcription factor 4 (OCT4) and
Wnt. For example, overactivation of the Wnt/β-catenin pathway
leads to the transformation of intestinal crypt stem cells into
CSCs (19).
Both normal stem cells and CSCs reside in specific
microenvironments called niches that are mainly composed of
fibroblasts and endothelial, mesenchymal and immune cells, are
crucial for the regulation of their self-renewal, activation and
differentiation (22) and contribute to drug resistance of the
tumor (23).
CSC surface markers have not been clearly established, mainly
because of significant inter- and intra-tumor heterogeneity.
CSCs isolated from different cancers share markers typical of
physiological stem cells, such as CD24, CD44, CD90, CD123,
CD133, OCT4, SOX2, Nanog, Nestin, c-kit, ABCG2, and ALDH1
(17, 24). In many cases CSCs can only be identified by a
combination of different markers, and most of the CSCs markers
are also expressed by normal stem cells (17, 25).
CSCs have the ability to form multicellular three-dimensional
floating spheres in vitro when grown in non-adherent serum-
free conditions (26, 27). This in vitro assay allows the
growth and propagation of CSCs, and their subsequent
molecular characterization.
The gold standard assay for identifying CSCs is serial tumor
transplantation at limited dilutions in immunodeficient mice,
which can assess both self-renewal andmultipotency of a putative
CSC subpopulation (26). Caveats reside in the choice of suitable
CSC surface markers for the isolation of CSCs for transplantation
and technical issues such as the dissociation of the tumor
mass, which inevitably results in the disruption of cell-to-cell
contacts, attachment to the extracellular matrix, and signals from
the microenvironment, with possible consequences on tumor-
initiating potential.
Recently developed experiments of genetic lineage tracing
and cell ablation have overcome some of these limitations and
confirmed in situ that many solid tumors contain stem cells in
dedicated niches (20, 28–30).
According to the CSC model, complete tumor eradication
requires a combination of conventional treatment directed
toward bulk tumor cells with CSC-targeted drugs to prevent
recurrence, resistance and metastasis, all of which are sustained
by the CSC population. The first idea of anti-CSC therapy was
based on early observation that leukaemic cells were blocked
in an undifferentiated state. Drugs able to induce terminal
differentiation of CSCs were thus proposed (differentiation
therapy), with successful applications in patients with leukemia
(31). However, limited evidence of differentiation therapy efficacy
is available in solid tumors [revised in (32)]. A recent study
in osteosarcoma stem cells demonstrated that the ROCK
inhibitor fasudil significantly suppressed cell growth in vitro and
tumourigenicity in vivo by inducing cell differentiation (33).
In cultured CSCs of non-small cell lung cancer, an inhibitor
of GSK3β exhibited a strong antiproliferative effect (34). In
glioblastoma and neuroblastoma the inhibition of AKT/mTOR
pathway selectively targeted the CSC population (35).
Another strategy is based on antibodies targeting CSCs, but
the main limitation of this approach resides in the identification
of reliable CSC-associated antigens and in possible damage to
normal stem cells. The use of markers differentially expressed on
normal stem cells and CSCs has allowed the specific targeting
of leukemia stem cells in acute myeloid leukemia (36). An
attractive alternative to directly targeting CSCs is represented
by targeting their niche, e.g., by blocking stem cell niche
signals (10).
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TABLE 1 | Published studies describing isolation of TSCs from human pituitary tumors.
Study Ability to
grow as cell
spheres
Expression
of stem
cells
markers
Expression of
pituitary
specific
markers
Ability to
self-renew
Differentiation
in pituitary
hormone-
producing
cells
Resistance to
chemotherapeutics
Resistance
to DAs/SSAs
High
efflux
capacity
In vivo
tumourigenicity
Mouse Zebrafish
Xu et al. (38) Yes Yes Yes Yes Yes Yes ND ND Yes ND
Chen et al. (39) Yes Yes ND Yes ND ND ND ND Yes ND
Mertens et al. (40) Yes Yes ND Yes Yes ND ND Yes NO ND
Manoranjan et al. (41) Yes Yes ND Yes ND ND ND ND Yes ND
Würth et al. (42) Yes Yes ND Yes Yes ND NO ND NO Yes
Peverelli et al. (43) Yes Yes Yes Yes ND ND NO ND ND Yes
The assessment of the main features typical of CSCs is reported. ND, Not Determined.
TABLE 2 | Stem cell markers expressed in TSCs spheres isolated from human pituitary tumors.
Xu et al. (38) Chen et al. (39) Mertens et al. (40) Manoranjan et al. (41) Würth et al. (42) Peverelli et al. (43)
CD133 X X X
CD15 X
CD90 X X
CXCR4 X
DLL1 X
JAG2 X
KLF4 X
MSI X
NANOG X
Nestin X X X X X
NOTCH1 X
NOTCH4 X
OCT4 X X X
SOX2 X X X
TUMOR STEM CELLS (TSCs) IN PITUITARY
TUMORS
The CSC theory was initially developed for malignant tumors in
which CSCs were originally isolated and characterized. However,
the identification of normal stem cells in the adult pituitary gland
[revised in (37)] has prompted the investigation of the presence
of a CSC subpopulation in benign pituitary tumors. In the last
decade, experimental evidence has accumulated demonstrating
that it is possible to isolate cells from human pituitary tumors
that fulfill some or all the features typical of CSCs, namely,
clonogenic ability in vitro, expression of stem cell markers, ability
to grow as rounded cell spheres, multipotency, resistance to
chemotherapeutic agents, high efflux capacity, and propagation
of tumor tissue following xenotransplantation (Tables 1, 2). Since
pituitary tumors are mostly benign, these cells are more correctly
referred to as ‘tumor stem cells’ (TSCs) (44).
Isolation of TSCs From Pituitary Tumors
The first study describing a population of cells in pituitary
tumors presenting CSC properties was published in 2009 (38).
These cells, isolated from one NFPT and one GH-secreting
tumor, were able to form floating spheres when grown in
stem cell-permissive medium (DMEM/F12, B27 supplement,
bFGF, and EGF) (Figure 1), as described for normal pituitary
stem cells (45); expressed stem cell markers (OCT4, CD133
NOTCH4 and Nestin) (Table 2) and pituitary-specific markers
(PIT1 and <GSU); and could be subcloned in culture (self-
renewal assays) and differentiated into pituitary hormone-
producing cells. In addition, these TSCs displayed resistance to
chemotherapeutics (carboplatin and etoposide), that might be
due to the upregulation of anti-apoptotic genes (38) or to an
upregulation of multidrug transporters ABCB1 and ABCG2 (40).
These TSCs were able, when transplanted into the forebrains
of immunodeficient NOD/SCID mice, to give rise to tumors
that recapitulated the phenotypes of human primary tumors,
although convincing evidence was not provided. This study
presents some inconsistencies regarding hormone production by
TSCs derived from NFPT that can produce LH and by TSCs
derived from GH-secreting tumors that can secrete PRL and
TSH after stimulation. These observations suggest that spheres
may include differentiated, hormone-producing cells derived
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FIGURE 1 | The figure shows a schematic representation of the isolation and characterization of TSCs from surgically removed pituitary tumors. Human pituitary
tumors tissues, obtained by the transsphenoidal route, are mechanically and enzymatically (with 2 mg/mL collagenase in DMEM) dissociated (A). To obtain TSCs
spheres, tumor cells are resuspended in stem cell permissive medium (serum-free DMEM/F12 1:1 medium) in the presence of 20 ng/ml basic fibroblast growth factor
(bFGF), 20 ng/ml epidermal growth factor (EGF), B27, 100 units/ml penicillin, 100 mg/ml streptomycin and 0.25µg/ml fungizone (B). About 2 weeks after cell seeding
in stem cell permissive medium, non-adherent round cell spheres appear in a subset (about 70%) of cultured tumor cells (C). Spheres are then phenotypically
characterized for self-renewal ability, stem-cell markers expression, biological behavior and in vivo tumourigenicity (D). Scale bar 50µm.
from the differentiation of stem cells, even if cultured in stem
cell-permissive medium.
The hypothesis of the existence of pituitary TSCs was further
supported 5 years later by a study by Chen et al. (39) that
isolated pituitary tumor cells that were grown as floating spheres
in vitro, expressed the neural stem/progenitor cell markers
CD133 and Nestin, and were able to generate daughter cells that
could differentiate into three neural lineages (Tables 1, 2). These
cells generated slow-growing, synaptophysin-positive tumors
after subcutaneous xenotransplantation into SCID mice. The
limitations of this study reside in the choice of markers, whose
specificity is controversial, and in the lack of demonstration of
production of pituitary hormones.
One year later, Mertens and colleagues found a side
population (SP) composed of cells with high efflux capacity
(40) in pituitary tumors, as previously described for normal
pituitary stem cells (46). The SP, when purified from endothelial
and immune cells, expressed a panel of CSC markers, including
CD44, CXCR4, KIT, KLF4, SOX2, and Nestin, overexpressed
genes related to epithelial-to-mesenchymal transition (EMT) and
angiogenesis, formed floating spheres in culture, had clonogenic
potential and differentiated into pituitary hormone-producing
cells. However, in contrast with previous studies, these cells were
not able to originate tumors following xenotransplantation into
NOD-SCID mice (40) (Tables 1, 2). Tumor-forming potential in
mice was instead exhibited by an SP with high efflux capacity that
was identified in the mouse pituitary corticotrope tumor cell line
AtT20 (40) and by a subpopulation of murine stem-like cells that
was isolated from pituitary tumors spontaneously occurring in
Rb±mice (47).
A subsequent study (41) on differential gene expression
profiles and flow cytometric characterization identified CD15,
a CSC marker in other brain tumors, as a marker for
pituitary TSCs. The CD15+ cell subpopulation displayed high
sphere-forming capacity, elevated SOX2 gene expression and
tumourigenic potential in mice.
In contrast, the lack of tumor-generating ability of human
pituitary TSCs in mice was reported in another study, in which
stem-like cells were successfully isolated from 38 of 56 pituitary
tumors of different types (GH-, GH/PRL-, and ACTH-secreting
tumors and NFPTs) (42).
Since contrasting data have been reported about the in vivo
tumourigenicity in mice (Table 1), it can be hypothesized that
the failure of this assay is due to the typical clinical behavior of
pituitary tumors, which is characterized by slow growth, as well
as to methodological caveats related to the use of in vitro cultures
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of stem cells prior to transplantation or to the isolation of stem
cell populations with different proliferative rates. Moreover, we
can speculate that benign tumors may depend more on their
niche than malignant tumors, and thus the lack of a proper
microenvironment in mice can explain the failure of tumor
formation after xenograft (48). In addition, the in vivo results
of the available studies remain questionable and not entirely
convincing. The major issues reside in the excessive number of
transplanted cells, lack of data on long-term growth and serial in
vivo transplantation.
On the other hand, the pro-angiogenic and invasive potential
of pituitary TSCs was successfully demonstrated in zebrafish
embryos (42, 43) (Table 1), an alternative model that allows the
detection of in vivo biological behaviors of tumor cells in a shorter
time than that in mice, which is more compatible with the slow
growth rate of pituitary tumors.
Würth et al. (42) and Peverelli et al. (43) isolated TSCs
growing as floating spheres from a high number of NFPTs
(n = 32) with a success rate of sphere formation nearly
identical to that which was previously reported. In both of
these studies, the sphere-forming cells were able to self-renew
in culture and expressed several markers of stemness, including
pluripotent embryonic stem cell markers (SOX2, OCT4, KLF4,
andNestin) (Table 2). In addition, NFPT-derived TSCs expressed
embryonic pituitary-specific transcription factors involved in
gonadotroph differentiation (DAX1, SF1, and EGR1), which is
consistent with the gonadotroph origin of most NFPTs (43),
and mature hormones (38, 40). Interestingly, the expression of
pituitary tumor-specific receptors, SS receptors type 2 (SSTR2)
and 5 (SSTR5) or DRD2 has been detected in cells in the
spheres (42, 43). These observations suggest the presence of
committed precursors in spheres cultured in vitro in stem cell-
permissive medium.
Pituitary TSCs demonstrate long-term proliferation ability
of up to 1–2 months in culture (42, 43), in striking contrast
with differentiated cells from the same tumors, which actively
proliferate only for 1 week (43), and with pituitary cell primary
cultures, which usually survive in vitro for only a few days.
The analysis of stem cell marker expression in NFPT tissues
revealed the expression of SOX2, OCT4, KLF4, and EGR1 (43).
Interestingly, SOX2-positive cells, sparsely distributed in the
tissue sections and representing approximately 4% of pituitary
cells of NFPT tissues, were negative for pituitary hormones,
and only 1% of SOX2+ cells co-expressed LH (43). Similarly,
in GH-secreting tumor tissues, no co-expression of GH with
SOX2, OCT4, or Nestin was observed (42). Overall, these data
indicate the presence of a hormone-negative cell subpopulation
expressing stem cell markers in pituitary tumors.
Role of Pituitary TSCs in Pituitary Tumor
Resistance to Medical Therapy
The molecular basis of pituitary tumor resistance to
pharmacological therapy with DAs and SSAs is still poorly
understood. The possible involvement of a drug-resistant TSC
population has been independently investigated by two different
groups with similar findings (Table 3).
TABLE 3 | The table summarizes the results of the published studies supporting
or not a possible role of pituitary TSCs in human pituitary tumors clinical behavior.
Role of TSCs
Yes No
Resistance to
medical therapy
(38) (carboplatin, etoposide) (43) (BIM53097, BIM23120);
(42) (BIM-23A760)
Invasiveness (39, 40, 42, 43) –
Recurrence (41) (49)
Peverelli et al. (43) tested the antiproliferative effects of the
specific DRD2 agonist BIM53097 and SSTR2 agonist BIM23120
on cultured cells derived from NFPT tissues immediately after
dispersion prior to sphere formation and on TSC spheres.
Cell proliferation and cell cycle progression were evaluated by
measuring BrdU incorporation, cyclin D3 and cyclin-dependent
kinase inhibitor p27 levels. They found that in the subset of
NFPTs in which DRD2 or SSTR2 agonists inhibited bulk tumor
cell proliferation, the antiproliferative effect was maintained in
the corresponding spheres.
In agreement, Würth et al. (42) observed a reduction in TSC
survival measured by MTT assay upon somatostatin/dopamine
chimera BIM-23A760 incubation.
Overall, these results suggest that pituitary TSCs are not
characterized by resistance to the drugs currently used in the
treatment of pituitary tumors, ruling out the hypothesis that these
cells are responsible for the pharmacological resistance observed
in a subset of patients, as also supported by the lack of difference
in the frequency of TSC sphere formation between NFPTs that
were resistant or sensitive to these drugs in vitro (43).
On the other hand, based on these data, pituitary TSCs can
be considered a good target for pharmacological approaches
using DAs and SSAs, supporting the use of these agents in
adjuvant medical therapy. In agreement, it has been reported
that DA therapy in patients with NFPTs was associated with a
decreased prevalence of residual tumor regrowth after surgical
resection (50).
Interestingly, TSC spheres derived from resistant NFPTs were
significantly larger than those obtained from sensitive ones (43),
suggesting an increased proliferative activity of TSCs in resistant
tumors, which is consistent with the notion that resistance is
associated with increased pituitary tumor aggressiveness.
Role of Pituitary TSCs in Pituitary Tumor
Invasiveness
Since only approximately 70% of pituitary tumors gave rise
to TSC spheres in culture (42, 43), a possible correlation
between this ability and clinical tumor behavior has been
hypothesized (Table 3). Comparison of clinicopathological and
radiological features revealed that the formation of spheres was
positively associated with cavernous sinus invasion, whereas
no correlation with sex, age, tumor size, Ki67 and extrasellar
extension was found (43). Accordingly, the number of CD133+
cells was significantly increased in invasive tumors compared
that of non-invasive pituitary tumors, as determined by both
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immunocytochemistry and flow cytometry assays (39). In this
respect, it is of interest to note that the SP isolated from
pituitary tumors by Mertens et al. (40) overexpressed gene
clusters involved in cell motility and migration. In addition,
pituitary TSCs xenografted into zebrafish embryosmigrated from
the site of injection and showed strong invasive behavior (42, 43).
Together, these data suggest that pituitary TSCs may
contribute to the local invasiveness of pituitary tumors.
Further studies are required to evaluate the differential cell
migration and invasion ability of TSCs in comparison to that of
differentiated bulk tumor cells. Moreover, since it has been shown
that DAs and SSAs exert inhibitory effects on the migration and
invasion of pituitary tumor cells (51, 52), it would be of great
interest to test whether these effects are maintained in TSCs,
possibly supporting the use of these agents in the control and
prevention of tumor local invasiveness.
Role of Pituitary TSCs in Pituitary Tumor
Recurrence
There is little data available about a possible contribution of
pituitary TSCs to tumor recurrence, according to the CSC
model (Table 3).
Manoranjan and colleagues found an enrichment of CD15
expression in recurrent tumors compared to that of their
matched primary tumors (41), suggesting that CD15+ TSCs may
promote tumor relapse.
Yunoue et al. (49) reported no correlation between the
expression of CD133 in pituitary tumors and the postoperative
recurrence rate. Although CD133 is considered a common
marker of CSCs in different tumors and its presence has been
detected in pituitary tumors (39, 53), it is worth noting that
contrasting data have been reported on CD133 expression in TSC
spheres derived from pituitary tumors, ranging from positive
to negative or low expression (38, 39, 41–43, 54), highlighting
the need for the identification of more precise markers for
pituitary TSCs.
Role of Pituitary TSCs in Tumourigenesis
and Tumor Progression
Long-term proliferation ability and tumourigenic potential in
animal models exhibited by pituitary TSCs suggest that TSCs
may play a major role in the initiation process of pituitary
tumourigenesis, as well as in pituitary tumor growth, but this
hypothesis has yet to be proven.
Recently, non-secreting and aggressive pituitary tumors have
been found in mice bearing deletion of the LATS gene, a kinase
belonging to the Hippo pathway (LATS/YAP/TAZ signaling),
which is crucial in the maintenance of active pituitary stem
cell state and in the inhibition of differentiation (55). These
murine tumors were composed predominantly of SOX2+ cells,
suggesting that loss of LATS, obtained by genetic manipulation,
drives deregulation of SOX2+ pituitary stem cells, leading
to tumor formation. Interestingly, overexpression of Hippo
pathway components has been reported in the SP of pituitary
tumors (40).
In another pituitary tumor type, adamantinomatous
craniopharyngioma (ACP), strong evidence supports a paracrine
role of TSCs in tumor development and growth by stimulation
of the proliferation of adjacent cells. Genetic linage tracing
experiments in a mouse model of ACP showed that SOX2+
cells targeted with mutant β-catenin did not autonomously give
rise to the tumor mass but instead generated the tumor from
neighboring cells in a paracrine manner (44, 56, 57).
CONCLUSIONS
In the past decade, the existence of a population of stem
cells in pituitary tumors has been established, but the role of
these pituitary TSCs in tumor initiation, progression, recurrence
and resistance to pharmacological therapy, analogous to the
CSC model, needs to be further elucidated. Although pituitary
TSCs are not responsible for resistance to DAs and SSAs, their
presence seems to be associated with tumor invasiveness and
possibly recurrence.
The presence of stem cells in benign pituitary tumors may
suggest that CSCs are not associated with malignancy. However,
studies on CSCs in pituitary carcinomas or atypical pituitary
adenomas would be required to clarify their role in pituitary
tumor aggressiveness.
Admittedly, most of the published studies investigated TSCs
in NFPTs, whereas little information is available for the other
types of pituitary tumors.
Further studies aimed to clarify the relationship between
tumor-initiating cells and pituitary TSCs are needed. Once the
pituitary TSCs and the mechanisms involved in their regulation
have been fully characterized, new therapeutic strategies targeting
TSCs and new biomarkers predicting pituitary tumor clinical
behavior could be developed.
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